Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer. This continues Curve’s strong momentum expanding its leadership team following the recent appointments of Andre Hoekema and Cora Griffin, joining as Chair of the Board and Head of Business Development respectively.

Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]

Research led by Curve CSO Professor Ali Tavassoli’s laboratory at University of Southampton Landmark paper on dual HIF-1 and HIF-2 inhibitor that works by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β Southampton, UK, 26 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening […]